Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting
Eisai learns from Biogen’s Aduhelm disaster
Neurocrine blows fresh wind in Voyager's sails with $175M upfront for CNS capsid collab
5 FDA decisions to watch in the first quarter
*please scroll down for all the latest news*
